Skip to content

Persista Bio

Implantable cell therapy for Type 1 diabetes

Raised to date

Not disclosed

1 Form D filing, none with a dollar amount

Last filed
Apr 29, 2026

About

Persista Bio is a seed-stage company developing the O2Line system, a long-term cell implant that regulates blood sugar automatically in Type 1 diabetes. The implant pairs an electrochemical oxygen generator with a core-shell nanofibrous capsule that holds the cells. It is in preclinical testing, and the company licenses its technology from Cornell University and Giner, Inc.

Oxygenated encapsulation intended to let stem cell therapies work without immunosuppression.

Funding

No dollar amounts disclosed.

  • EquityFiled Apr 29, 2026Form D
    None sold/ no target

Product

O2Line

Cell therapy implant

A long-term implantable cell delivery system that combines an implantable electrochemical oxygen generator with a core-shell nanofibrous encapsulation capsule to regulate blood glucose.

  • Implantable electrochemical oxygen generator
  • Core-shell nanofibrous cell encapsulation capsule
  • Aims to avoid immunosuppression

Built for

People with Type 1 diabetes

People on file